RhumbLine Advisers
FLGT icon

RhumbLine Advisers’s Fulgent Genetics FLGT Stock Holding History

RhumbLine Advisers’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Sell
26,102
-1,043
-4% -$17.7K ﹤0.01% 2724
2026
Q1 		$432K Sell
27,145
-1,518
-5% -$32.9K ﹤0.01% 2706
2025
Q4 		$753K Sell
28,663
-4,264
-13% -$111K ﹤0.01% 2387
2025
Q3 		$744K Sell
32,927
-212
-0.6% -$4.37K ﹤0.01% 2424
2025
Q2 		$659K Buy
33,139
+785
+2% +$15.3K ﹤0.01% 2494
2025
Q1 		$547K Sell
32,354
-34,049
-51% -$580K ﹤0.01% 2517
2024
Q4 		$1.23M Sell
66,403
-395
-0.6% -$7.71K ﹤0.01% 2138
2024
Q3 		$1.45M Sell
66,798
-1,412
-2% -$31.6K ﹤0.01% 2069
2024
Q2 		$1.34M Buy
68,210
+637
+0.9% +$13.3K ﹤0.01% 2086
2024
Q1 		$1.47M Buy
67,573
+1,027
+2% +$25.5K ﹤0.01% 2062
2023
Q4 		$1.92M Buy
66,546
+657
+1% +$17.6K ﹤0.01% 1922
2023
Q3 		$1.76M Buy
65,889
+817
+1% +$27.9K ﹤0.01% 1916
2023
Q2 		$2.41M Sell
65,072
-811
-1% -$28.3K ﹤0.01% 1799
2023
Q1 		$2.06M Buy
65,883
+1,717
+3% +$55.3K ﹤0.01% 1793
2022
Q4 		$1.91M Buy
64,166
+1,873
+3% +$67K ﹤0.01% 1809
2022
Q3 		$2.38M Buy
62,293
+2,495
+4% +$125K ﹤0.01% 1661
2022
Q2 		$3.26M Buy
59,798
+4,627
+8% +$254K ﹤0.01% 1491
2022
Q1 		$3.44M Buy
55,171
+2,115
+4% +$139K ﹤0.01% 1545
2021
Q4 		$5.34M Buy
53,056
+293
+0.6% +$25.8K 0.01% 1320
2021
Q3 		$4.75M Sell
52,763
-4,583
-8% -$417K 0.01% 1390
2021
Q2 		$5.29M Buy
57,346
+13,288
+30% +$1.06M 0.01% 1399
2021
Q1 		$4.26M Buy
44,058
+8,966
+26% +$926K 0.01% 1498
2020
Q4 		$1.83M Buy
35,092
+8,085
+30% +$338K ﹤0.01% 1894
2020
Q3 		$1.08M Buy
+27,007
New +$845K ﹤0.01% 1964

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RhumbLine Advisers's FLGT Position: Q2 2026 in Review

RhumbLine Advisers reduced its Fulgent Genetics (FLGT) stake by 3.8% in Q2 2026, selling an estimated $17.7K and leaving 26,102 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #2724.

RhumbLine Advisers first reported a position in FLGT in Q3 2020 and has held it in 24 quarters since. The position peaked at $5.34M in Q4 2021. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • RhumbLine Advisers held 26,102 shares of Fulgent Genetics worth $536K as of Q2 2026.
  • RhumbLine Advisers sold 1,043 Fulgent Genetics shares in Q2 2026, an estimated $17.7K.
  • Fulgent Genetics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2724 holding.
  • RhumbLine Advisers first reported a position in Fulgent Genetics in Q3 2020 and has held it in 24 quarters since.
  • RhumbLine Advisers's Fulgent Genetics position peaked at $5.34M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.